Introducing a novel approach to targeted protein degradation, biological PROTACs (bioPROTACs) represent a promising alternative to traditional PROTACs. By engineering intracellular proteins fused with target-binding domains and E3 ubiquitin ligases, bioPROTACs offer enhanced specificity and efficacy in degrading challenging targets like KRAS and proliferating cell nuclear antigen (PCNA). This innovative technology not only provides powerful tools for understanding degradation mechanisms and target biology but also holds significant potential for therapeutic applications, offering new avenues for treating diseases by precisely modulating protein levels and functions.
bioPROTACs consist of three components in a single mRNA:
- E3 ligase domain
- Target protein binding domain or nanobody
- Linker connecting both entities
Lifesensors offers unique and physiologically relevant target ubiquitination and degradation assays that allows rapid characterization of bioPROTACs for their specificity and potency.
LifeSensors helps you study the bioPROTACs to make breakthrough discoveries and pave the way to novel therapeutics.